RxDoctor Payments Data

Katherine Love

Family · Circleville, OHNPI 1093059347

Payments from drug & device makers

$1,535in general payments, 2019–2025

Across 32 payments — averaging $47.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$528
  • Abbott$476
  • Boehringer Ingelheim$252
  • Novartis$108
  • Pfizer$79
  • Novo Nordisk$40
  • plus $52 from 2 others

What the payments were for

  • Food & beverage$1,51699%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic6$528
Abbott6$476
Boehringer Ingelheim4$252
Novartis7$108
Pfizer4$79
Novo Nordisk2$40
Johnson & Johnson2$37
Amgen1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,535 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$23,387
Medicare patients
242
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$109,530
EntrestoSacubitril/Valsartan59$56,598
JardianceEmpagliflozin73$56,380
XareltoRivaroxaban35$36,533
Repatha SureclickEvolocumab20$14,503
Ranolazine ErRanolazine14$1,232
Atorvastatin Calcium96$900
ClopidogrelClopidogrel Bisulfate116$783
Flecainide Acetate16$713
Metoprolol Succinate63$563
Carvedilol62$485
Rosuvastatin Calcium35$403
Spironolactone66$398
Losartan Potassium35$363
Metoprolol Tartrate77$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$79$109,530131 claims
NovartisEntresto$108$56,59859 claims
Boehringer IngelheimJardiance$252$56,38073 claims
Johnson & JohnsonXarelto$37$36,53335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.

Other family in Circleville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →